share_log

ABVC BioPharma, Inc. (OTCMKTS:ABVC) Forecasted to Post Q1 2023 Earnings of ($0.05) Per Share

ABVC BioPharma, Inc. (OTCMKTS:ABVC) Forecasted to Post Q1 2023 Earnings of ($0.05) Per Share

ABVC BioPharma, Inc.(OTCMKTS: ABVC)预计2023年第一季度每股收益为0.05美元
Defense World ·  2023/01/20 02:21

ABVC BioPharma, Inc. (OTCMKTS:ABVC – Get Rating) – Zacks Small Cap issued their Q1 2023 earnings estimates for ABVC BioPharma in a research report issued on Wednesday, January 18th. Zacks Small Cap analyst M. Marin anticipates that the company will post earnings of ($0.05) per share for the quarter. The consensus estimate for ABVC BioPharma's current full-year earnings is ($0.56) per share. Zacks Small Cap also issued estimates for ABVC BioPharma's Q2 2023 earnings at ($0.06) EPS, Q3 2023 earnings at ($0.05) EPS and Q4 2023 earnings at ($0.04) EPS.

ABVC BioPharma, Inc.(OTCMKTS: ABVC — 获取评级)——Zacks Small Cap在1月18日星期三发布的一份研究报告中发布了ABVC BioPharma2023年第一季度的收益预期。Zacks Small Cap分析师M. Marin预计,该公司将公布本季度每股收益(0.05美元)。ABVC BioPharma当前全年收益的共识估计为每股收益(0.56美元)。Zacks Small Cap还公布了ABVC BioPharma2023年第二季度每股收益(0.06美元)、2023年第三季度收益为每股收益(0.05美元)和2023年第四季度每股收益(0.04美元)的估计。

Get
获取
ABVC BioPharma
ABVC 生物制药
alerts:
警报:

Separately, Maxim Group cut shares of ABVC BioPharma from a "buy" rating to a "hold" rating in a report on Wednesday, November 16th.

另外,Maxim集团在11月16日星期三的一份报告中将ABVC BioPharma的股票评级从 “买入” 评级下调至 “持有”。

ABVC BioPharma Price Performance

ABVC BioPharma 价格表现

ABVC opened at $0.78 on Thursday. The stock has a market capitalization of $25.46 million, a PE ratio of -1.15 and a beta of 0.50. The firm's fifty day moving average price is $0.75 and its 200 day moving average price is $0.80. ABVC BioPharma has a 12-month low of $0.50 and a 12-month high of $3.17.
ABVC周四开盘价为0.78美元。该股的市值为2546万美元,市盈率为-1.15,beta值为0.50。该公司的五十天移动平均线价格为0.75美元,其200天移动平均线价格为0.80美元。ABVC BioPharma创下12个月低点0.50美元,12个月高点为3.17美元。

ABVC BioPharma (OTCMKTS:ABVC – Get Rating) last posted its quarterly earnings results on Monday, November 14th. The company reported ($0.11) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.09. The company had revenue of $0.04 million during the quarter, compared to analyst estimates of $0.03 million.

ABVC BioPharma(OTCMKTS: ABVC — 获取评级)最后一次公布季度财报是在11月14日星期一。该公司报告本季度每股收益(EPS)(0.11美元),比市场普遍预期的(0.20美元)高出0.09美元。该公司在本季度的收入为4万美元,而分析师的估计为03万美元。

ABVC BioPharma Company Profile

ABVC BioPharma 公司简介

(Get Rating)

(获取评分)

ABVC BioPharma, Inc, a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase I/II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for attention deficit hyperactivity disorder; ABV-1703 has completed Phase I clinical trials for the treatment of pancreatic cancer; ABV-1702 has completed Phase I clinical trials to treat myelodysplastic syndromes; ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients; and ABV-1701 Vitargus for the treatment of retinal detachment or vitreous hemorrhage.

ABVC BioPharma, Inc是一家临床阶段的生物制药公司,开发药物和医疗器械,以满足美国未得到满足的医疗需求。该公司正在开发一种治疗三阴性乳腺癌的联合疗法 ABV-1501,该药物正处于 I/II 期临床试验;ABV-1504 已完成重度抑郁症的 II 期临床试验;ABV-1505 正在进行注意力缺陷多动障碍的 II 期临床试验;ABV-1703 已经完成了治疗骨髓增生异常综合征的 I 期临床试验;ABV-1601 正在进行治疗骨髓增生异常综合征的 I 期临床试验;正在进行治疗 I/II 期临床试验癌症患者的抑郁症;以及 ABV-1702ABV-1701 Vitargus 用于治疗视网膜脱离或玻璃体出血。

Further Reading

进一步阅读

  • Get a free copy of the StockNews.com research report on ABVC BioPharma (ABVC)
  • Exxon Mobil Stock: Within Striking Distance Of Buy Point
  • High-Dividend-Yielding BHP Sees China Driving '23 Growth
  • Is Airbnb Setting Up To Rally 38%, As Analysts Are Forecasting?
  • Does a Price Cut for Tesla Vehicles Mean the Same for TSLA Stock?
  • Microsoft Layoffs Signal Layoffs for Other Tech Companies?
  • 免费获取 StockNews.com 关于 ABVC BioPharma(ABVC)的研究报告的副本
  • 埃克森美孚股票:距离买入点仅几步之遥
  • 高股息收益的必和必拓认为中国将推动 “23” 的增长
  • Airbnb是否准备像分析师所预测的那样上涨38%?
  • 特斯拉汽车降价对TSLA股票意味着同样的吗?
  • 微软裁员预示着其他科技公司的裁员?

Receive News & Ratings for ABVC BioPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABVC BioPharma and related companies with MarketBeat.com's FREE daily email newsletter.

接收 ABVC BioPharma Daily 的新闻和评级 -在下面输入您的电子邮件地址,通过Marketbeat.com的免费每日电子邮件时事通讯接收ABVC BioPharma及相关公司的最新新闻和分析师评级的简明每日摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发